International Journal of Pharmacy and Pharmaceutical Science

ISSN Print: 2664-7222
ISSN Online: 2664-7230
IJPPS 2025; 7(2): 765-772
www.pharmacyjournal.org
Received: 17-10-2025
Accepted: 20-11-2025

Divya Rajesh Gunjal
B.R. Harne College of Pharmacy, Karav, Vangani (W), near Badlapur, Taluka Ambernath, Maharashtra, India

Snehal Banote
Department of Pharmaceutical Analysis, B.R. Harne College of Pharmacy, Vangani, Maharashtra, India

Gita Mohire
Department of Pharmaceutical Analysis, B.R. Harne College of Pharmacy, Vangani, Maharashtra, India

Corresponding Author:
Divya Rajesh Gunjal
B.R. Harne College of Pharmacy, Karav, Vangani (W), near Badlapur, Taluka Ambernath, Maharashtra, India

Critical review of simultaneous analytical methods for telmisartan and amlodipine

Divya Rajesh Gunjal, Snehal Banote and Gita Mohire

DOI: https://www.doi.org/10.33545/26647222.2025.v7.i2i.274

Abstract
The simultaneous estimation of telmisartan and amlodipine in fixed-dose combination products presents persistent analytical challenges arising from unequal dose ratios, overlapping spectral characteristics, and increasing regulatory expectations for method robustness. This critical review systematically evaluates spectroscopic and chromatographic approaches reported for the concurrent analysis of these antihypertensive agents, with emphasis on their theoretical foundations, analytical strengths, and inherent limitations. Spectroscopic methods, including derivative, multi-wavelength, and chemometric-assisted techniques, offer simplicity and cost efficiency but remain fundamentally constrained by spectral overlap and limited intrinsic selectivity. In contrast, chromatographic methods, particularly reverse-phase high-performance liquid chromatography, achieve superior analytical assurance through physical separation of analytes and demonstrate stronger alignment with regulatory validation requirements. A structured comparative synthesis highlights the distinct roles of each methodological class within a tiered analytical framework; wherein spectroscopic techniques serve supportive or preliminary functions and chromatographic methods provide confirmatory and regulatory-acceptable quantification. By integrating theoretical analysis, regulatory considerations, and future analytical trends, this review aims to support rational method selection and informed analytical decision-making for quality control and regulatory assessment of telmisartan-amlodipine combination products.

Keywords: Telmisartan, amlodipine, fixed-dose combination, simultaneous estimation, spectroscopic methods, chromatographic methods, RP-HPLC, analytical method comparison, pharmaceutical analysis, quality control

1. Introduction
Combination therapy is widely recommended in the management of hypertension to achieve effective blood pressure control when monotherapy is insufficient [27]. Fixed-dose combinations improve patient adherence and simplify dosing regimens, making them a preferred therapeutic option in clinical practice [26]. Among the commonly prescribed combinations, telmisartan and amlodipine are frequently formulated together in solid oral dosage forms for long-term treatment of hypertension [25].

The increasing production and use of telmisartan-amlodipine combination products necessitate stringent analytical control to ensure consistent drug content and product quality throughout manufacturing and shelf life [18]. Pharmaceutical analysis plays a critical role in verifying compliance with regulatory specifications, particularly for combination products where analytical complexity is greater than that of single-drug formulations [19]. Reliable analytical methods capable of simultaneously quantifying both active pharmaceutical ingredients are therefore essential for routine quality control.

From an analytical perspective, telmisartan and amlodipine exhibit markedly different physicochemical properties that influence method selection and performance [21]. Telmisartan is highly lipophilic with limited aqueous solubility, whereas amlodipine possesses comparatively higher polarity, resulting in challenges during simultaneous analysis [22]. In ultraviolet spectrophotometry, overlapping absorption spectra of the two drugs complicate direct measurement approaches and often necessitate mathematical or derivative techniques to improve selectivity [1].

Several spectrophotometric methods have been developed for the simultaneous estimation of telmisartan and amlodipine in tablet dosage forms. First-derivative spectrophotometric

methods have been reported to resolve overlapping spectra and enable simultaneous quantification [1]. Multi-wavelength and absorbance correction approaches have also been employed to enhance method applicability and simplicity [4]. Additionally, chemometric-assisted spectrophotometric techniques have been introduced to improve analytical performance in complex formulations containing multiple components [5]. Despite their advantages, spectrophotometric methods may exhibit limitations in sensitivity and robustness under stringent regulatory conditions [10].

To overcome these limitations, chromatographic techniques, particularly reverse-phase high-performance liquid chromatography, have been widely adopted for the simultaneous estimation of telmisartan and amlodipine [6]. RP-HPLC methods offer improved selectivity, precision, and reproducibility, making them suitable for routine quality control and regulatory testing [8]. However, reported chromatographic methods vary considerably with respect to mobile phase composition, detection wavelength, run time, and validation depth, which complicates objective evaluation of their suitability [6].

Although numerous analytical methods have been published, most studies focus on individual method development rather than systematic comparison [2]. Furthermore, inconsistencies in validation practices and incomplete adherence to International Council for Harmonisation guidelines have been observed across published reports [16]. The absence of a consolidated critical review specifically addressing simultaneous analytical methods for telmisartan and amlodipine highlights a clear gap in the pharmaceutical analysis literature.

The objective of the present review is to critically examine reported spectrophotometric and chromatographic methods for the simultaneous estimation of telmisartan and amlodipine in pharmaceutical dosage forms. Emphasis is placed on analytical principles, method performance, validation parameters, and regulatory considerations in line with ICH Q2(R1) requirements [16]. By synthesizing and evaluating existing analytical approaches, this review aims to provide a structured reference for researchers and quality control laboratories.

2. Drug-Related Analytical Properties of Telmisartan and Amlodipine

The physicochemical properties of active pharmaceutical ingredients play a critical role in determining the suitability and performance of analytical methods, particularly in the simultaneous estimation of combination drug products. Telmisartan and amlodipine exhibit distinct analytical behaviors that must be considered during method selection and evaluation.

Telmisartan is a highly lipophilic molecule with poor aqueous solubility, a property that significantly influences sample preparation and extraction efficiency in pharmaceutical analysis [21]. Its limited solubility in water often necessitates the use of organic solvents, which can affect both spectrophotometric response and chromatographic retention behavior [22]. In ultraviolet spectrophotometry, telmisartan exhibits absorbance in the lower UV region, which may result in reduced sensitivity or interference from excipients if appropriate wavelength selection is not applied [22].

Amlodipine, in contrast, demonstrates comparatively higher polarity and improved solubility in aqueous media, contributing to differences in analytical response when analyzed alongside telmisartan [23]. The ultraviolet absorption characteristics of amlodipine partially overlap with those of telmisartan, creating challenges in direct UV-based simultaneous estimation [24]. This spectral overlap is a primary reason for the adoption of derivative, multi-wavelength, and chemometric-assisted spectrophotometric techniques in reported analytical methods [1].

The disparity in polarity between telmisartan and amlodipine also affects chromatographic separation under reverse-phase conditions. Telmisartan typically exhibits stronger retention on nonpolar stationary phases due to its lipophilic nature, whereas amlodipine elutes earlier under similar chromatographic conditions [6]. Such differences necessitate careful optimization of mobile phase composition and pH to achieve adequate resolution without compromising run time or peak symmetry [8].

Additionally, both drugs exhibit sensitivity to analytical conditions such as solvent composition and pH, which can influence peak shape, baseline stability, and reproducibility [9]. These physicochemical considerations underscore the importance of selecting analytical methods that can accommodate the contrasting properties of telmisartan and amlodipine while maintaining compliance with regulatory performance criteria.

The analytical-relevant physicochemical properties of telmisartan and amlodipine that influence method selection and performance are summarized in Table 1 [21-24].

Table 1: Analytical-Relevant Physicochemical Properties of Telmisartan and Amlodipine

Parameter	Telmisartan	Amlodipine
Chemical class	Angiotensin II receptor antagonist	Dihydropyridine calcium channel blocker
Molecular weight (g/mol)	~514.6	~408.9
Polarity	Highly lipophilic	Moderately polar
Aqueous solubility	Practically insoluble in water	Slightly soluble in water
Organic solvent solubility	Freely soluble in methanol and acetonitrile	Soluble in methanol and ethanol
Log P (qualitative)	High	Moderate
UV absorption region (λmax)	Lower UV region	Mid-UV region
Spectral overlap tendency	Significant overlap with amlodipine	Partial overlap with telmisartan
Chromatographic behavior (RP-HPLC)	Higher retention on C18 columns	Lower retention compared to telmisartan
Analytical implication	Requires organic solvent systems and optimized wavelength selection	Contributes to spectral interference in UV methods

3. Fixed-Dose Combination-Specific Analytical Considerations:

Fixed-dose combination (FDC) products containing telmisartan and amlodipine are widely used for the management of hypertension due to their complementary therapeutic actions and improved patient compliance [1, 25]. From an analytical perspective, however,

such combinations introduce additional complexity compared to single-component formulations, necessitating carefully designed simultaneous estimation methods.

One of the primary analytical challenges in FDC formulations arises from the disparity in the concentration ratios of telmisartan and amlodipine within dosage forms. Amlodipine is typically present at significantly lower dose levels compared to telmisartan, which can result in reduced sensitivity and quantification difficulties when conventional analytical techniques are applied without optimization [27]. This imbalance often requires analytical methods with sufficient sensitivity to accurately quantify the lower-dose component without compromising the assay of the higher-dose drug.

Differences in physicochemical properties, as summarized in Table 1, further complicate simultaneous analysis. The contrasting polarity and solubility characteristics of telmisartan and amlodipine influence extraction efficiency, spectral behavior, and chromatographic retention, particularly in multi-component systems [21, 23]. In spectrophotometric methods, overlapping absorption spectra frequently lead to interference, making direct zero-order UV analysis unsuitable without the application of derivative or multi-wavelength techniques [24].

In chromatographic analysis, fixed-dose combinations demand optimized separation conditions to ensure adequate resolution between analytes and excipients. Variations in retention behavior between telmisartan and amlodipine necessitate careful selection of mobile phase composition and pH to avoid co-elution or peak asymmetry, which can compromise accuracy and precision [33]. Additionally, excipient matrices present in combination tablets may contribute to baseline noise or interfere with analyte detection if specificity is not thoroughly evaluated [19].

The analytical requirements for FDC products also place greater emphasis on method validation. Parameters such as specificity, linearity, and robustness become particularly critical in simultaneous estimation to ensure reliable quantification of both drugs under varied analytical conditions [16, 26]. Failure to adequately address these parameters has been identified as a common limitation in previously reported methods for combination products [18].

Overall, the analytical challenges associated with telmisartan-amlodipine fixed-dose combinations highlight the necessity for well-validated, selective, and sensitive analytical methods capable of addressing formulation complexity while meeting regulatory expectations.

The key analytical challenges associated with the simultaneous estimation of telmisartan and amlodipine in fixed-dose combination formulations are schematically illustrated in Figure 1.



Fig 1: Analytical challenges associated with the simultaneous estimation of telmisartan and amlodipine in fixed-dose combination formulations.

4. Spectroscopic Methods for Simultaneous Estimation of Telmisartan and Amlodipine

Spectroscopic techniques, particularly ultraviolet (UV) spectrophotometry, have been widely investigated for the simultaneous estimation of telmisartan and amlodipine due to their operational simplicity, low cost, and minimal instrumental requirements [10]. From a theoretical standpoint, the applicability of UV-based methods to this drug combination is primarily governed by the electronic absorption characteristics of both analytes and the extent of spectral overlap in the ultraviolet region [21, 24]. The overlapping absorption profiles of telmisartan and amlodipine necessitate the use of mathematical signal resolution approaches rather than direct absorbance measurements [1].

4.1 Zero-Order UV Spectrophotometric Approaches

Zero-order UV spectrophotometry is based on the direct measurement of absorbance at selected wavelengths corresponding to the absorption maxima of the analytes [10]. In the case of telmisartan and amlodipine, partial to significant overlap of absorption bands limits the selectivity of zero-order measurements when both drugs are present simultaneously [24]. Theoretical analysis indicates that such overlap increases the risk of mutual interference, particularly when one component is present at a substantially lower concentration, as is typical for amlodipine in fixed-dose combinations [27]. Consequently, zero-order methods are generally considered analytically weak for simultaneous estimation unless supplemented by correction strategies [2].

4.2Derivative Spectrophotometric Techniques

Derivative spectrophotometry enhances spectral resolution by mathematically transforming zero-order spectra into first or higher derivatives, thereby reducing the contribution of overlapping signals [1]. The theoretical advantage of derivative methods lies in the identification of zero-crossing points, where one analyte exhibits zero absorbance while the other retains measurable response [3]. For telmisartan-amlodipine combinations, first-derivative techniques have been reported to improve selectivity without requiring physical separation of components [1]. However, derivative transformations inherently amplify spectral noise, making method performance highly dependent on instrumental resolution and signal smoothing parameters [10].

4.3Multi-Wavelength and Absorbance Correction Methods

Multi-wavelength spectrophotometric methods are based on the simultaneous measurement of absorbance at multiple selected wavelengths followed by mathematical resolution using simultaneous equations [4]. The theoretical basis of these methods assumes linear additivity of absorbance contributions from each analyte at the selected wavelengths [2]. In telmisartan-amlodipine systems, careful wavelength selection is critical to minimize cross-interference arising from overlapping absorption bands [4]. Absorbance correction techniques operate on similar principles but require accurate estimation of interference factors, which may vary with solvent composition and instrumental conditions [9].

4.4 Chemometric-Assisted Spectroscopic Methods

Chemometric-assisted spectroscopic techniques employ multivariate data analysis to extract quantitative information from complex overlapping spectra [5]. The theoretical strength of these approaches lies in their ability to utilize full spectral datasets rather than discrete wavelengths, thereby improving information content and reducing reliance on strict wavelength selectivity [5]. In formulations containing telmisartan and amlodipine, chemometric models have been shown to theoretically enhance predictive capability even in the presence of additional components [6]. Nevertheless, these methods require advanced statistical expertise and robust calibration models, which may limit their routine applicability in conventional quality control environments [11].

4.5 Critical Theoretical Assessment of Spectroscopic Methods

From an analytical perspective, spectroscopic methods for the simultaneous estimation of telmisartan and amlodipine offer advantages in terms of simplicity and throughput but remain fundamentally constrained by spectral overlap and sensitivity limitations [10]. Many reported approaches rely heavily on mathematical manipulation rather than intrinsic selectivity, which can compromise robustness under variable analytical conditions [9]. Furthermore, theoretical evaluation suggests that UV-based methods may struggle to consistently meet stringent regulatory expectations for specificity and reliability in complex fixed-dose combination products [16]. As a result, while spectroscopic techniques remain relevant for preliminary assessment and routine screening, their theoretical limitations often necessitate the use of chromatographic techniques for confirmatory analysis [8].

A theoretical comparison of the major spectroscopic strategies employed for simultaneous estimation of telmisartan and amlodipine, highlighting their analytical principles, strengths, and inherent limitations, is summarized in Table 2.

Table 2: Theoretical comparison of spectroscopic approaches for simultaneous estimation of telmisartan and amlodipine

Spectroscopic approach	Analytical principle	Strategy for managing spectral overlap	Theoretical advantages	Inherent analytical limitations	Qualitative regulatory suitability
Zero-order UV spectrophotometry	Direct measurement of absorbance at selected wavelengths based on Beer-Lambert law	Relies on wavelength selection near individual absorption maxima	Conceptually simple and rapid; minimal mathematical processing [10]	Significant mutual interference due to overlapping absorption bands; poor selectivity at unequal dose ratios [24, 27]	Limited; generally unsuitable without mathematical correction [16]
Derivative spectrophotometry	Mathematical transformation of zero-order spectra into derivative spectra	Use of zero-crossing points to isolate individual analyte responses [1, 3]	Improved spectral resolution without physical separation; enhanced selectivity over zero-order methods [1]	Amplification of instrumental noise; dependence on signal smoothing and spectral quality [10]	Moderate; acceptable for routine screening but sensitive to variability [16]
Multi-wavelength methods	Simultaneous absorbance measurement at multiple wavelengths with mathematical resolution	Application of simultaneous equations assuming linear absorbance additivity [2, 4]	Simple theoretical framework; reduced spectral interference compared to single-wavelength methods [4]	Accuracy highly dependent on wavelength selection and spectral consistency [9]	Moderate; suitable under controlled conditions [16]
Absorbance correction techniques	Mathematical correction of overlapping absorbance contributions	Use of correction factors to compensate for interference [2]	Does not require spectral transformation; retains zero-order data [2]	Susceptible to error from solvent and pH-dependent spectral shifts [9]	Limited to moderate; robustness concerns under varied conditions [16]
Chemometric-assisted spectrophotometry	Multivariate statistical modeling of full spectral data sets	Extraction of quantitative information from highly overlapping spectra [5, 6]	Maximizes spectral information content; theoretically superior selectivity [5]	Requires complex model development and validation; limited routine applicability [11]	Moderate to high; dependent on model robustness and validation rigor [16]

5. Chromatographic Methods for Simultaneous Estimation of Telmisartan and Amlodipine

Chromatographic techniques, particularly reverse-phase high-performance liquid chromatography (RP-HPLC), represent the most widely accepted analytical approach for the simultaneous estimation of telmisartan and amlodipine in pharmaceutical dosage forms due to their superior selectivity and robustness [8]. From a theoretical perspective, chromatographic separation overcomes the fundamental limitation of spectroscopic methods by achieving physical separation of analytes prior to detection, thereby minimizing mutual interference arising from overlapping spectral characteristics [6].

5.1 Theoretical Basis of RP-HPLC Separation

RP-HPLC separation is governed by differential partitioning of analytes between a nonpolar stationary phase and a relatively polar mobile phase [9]. In telmisartan-amlodipine combinations, the pronounced difference in lipophilicity between the two drugs plays a critical role in chromatographic behavior. Telmisartan, being highly lipophilic, exhibits stronger interaction with C18 stationary phases and consequently longer retention times, whereas amlodipine, with comparatively higher polarity, elutes earlier under similar conditions [6]. This intrinsic difference forms the theoretical basis for effective chromatographic resolution in fixed-dose combination analysis.

5.2 Mobile Phase Composition and pH Considerations

Theoretical optimization of mobile phase composition is essential to balance retention, resolution, and peak symmetry for both analytes [8]. Organic modifiers such as methanol or acetonitrile are commonly employed to accommodate the poor aqueous solubility of telmisartan while maintaining adequate elution of amlodipine [9]. Mobile phase pH further influences analyte ionization state, which in turn affects retention behavior and selectivity. Improper pH selection may result in peak tailing, co-elution, or reduced reproducibility, particularly for amlodipine, which exhibits pH-dependent ionization characteristics [22]. These considerations highlight the importance of theoretical understanding of analyte-mobile phase interactions rather than empirical trial-and-error approaches.

5.3 Detection Strategies in Chromatographic Methods

Ultraviolet detection remains the most commonly employed detection mode in RP-HPLC analysis of telmisartan and amlodipine due to its simplicity and compatibility with routine quality control workflows [8]. However, the theoretical limitation of UV detection lies in its dependence on adequate chromophoric response and wavelength compromise when multiple analytes are monitored simultaneously [10]. Selection of a common detection wavelength inherently represents a trade-off between sensitivity for each component, particularly when one drug is present at significantly lower concentration levels, as is the case for amlodipine in fixed-dose combinations [27].

5.4 Analytical Strengths of Chromatographic Approaches

From an analytical standpoint, chromatographic methods offer several theoretical advantages over spectroscopic techniques. Physical separation significantly enhances specificity and reduces susceptibility to excipient interference, baseline noise, and matrix effects [19]. RP-HPLC methods are also theoretically more amenable to comprehensive validation in accordance with ICH Q2(R1) requirements, particularly for parameters such as specificity, precision, and robustness [16]. These attributes make chromatographic approaches the preferred choice for regulatory submissions and routine quality control of combination products.

5.5 Inherent Limitations and Practical Considerations

Despite their advantages, chromatographic methods are not without theoretical limitations. Method complexity, higher operational costs, and increased solvent consumption are intrinsic to HPLC-based analysis [9]. Additionally, variability in reported chromatographic conditions across the literature such as mobile phase composition, column selection, and run time complicates direct comparison of method suitability [6]. From a review perspective, these inconsistencies underscore the need for critical evaluation of chromatographic strategies rather than uncritical adoption of published procedures.

5.6 Critical Analytical Perspective

In comparison to spectroscopic methods, chromatographic techniques provide superior analytical assurance for the simultaneous estimation of telmisartan and amlodipine, particularly in complex fixed-dose combination matrices [8]. However, theoretical evaluation indicates that optimal method performance is highly dependent on rational selection of chromatographic parameters informed by analyte physicochemical properties [21-24]. The analytical superiority of RP-HPLC therefore arises not solely from instrumental capability but from informed method design aligned with regulatory expectations [16].

A theoretical comparison of reported chromatographic strategies for the simultaneous estimation of telmisartan and amlodipine, emphasizing analytical principles, strengths, and regulatory relevance, is presented in Table 3.

Table 3: Theoretical comparison of chromatographic approaches for simultaneous estimation of telmisartan and amlodipine

Chromatographic approach	Analytical principle	Basis of Analyte discrimination	Theoretical advantages	Inherent analytical limitations	Qualitative regulatory suitability
RP-HPLC with UV detection	Separation based on differential partitioning between nonpolar stationary phase and polar mobile phase	Differences in lipophilicity and retention behavior of telmisartan and amlodipine on C18 phases [6, 9]	High selectivity through physical separation; broad applicability to fixed-dose combinations [8]	Requires wavelength compromise for simultaneous detection; sensitivity imbalance for low-dose amlodipine [10, 27]	High; widely acceptable for routine QC and regulatory analysis [16]
RP-HPLC with pH-controlled mobile phase	Modulation of analyte ionization to optimize retention and resolution	pH-dependent interaction of analytes with stationary phase affecting elution order and peak shape [22]	Improved peak symmetry and resolution; enhanced method robustness [8]	Sensitive to minor pH variations; requires strict control of buffer conditions [9]	High; suitable when robustness is adequately demonstrated [16]
Multi-component RP-HPLC methods	Simultaneous chromatographic separation of more than two analytes	Exploitation of retention differences among multiple APIs in fixed-dose combinations [7]	Enables synchronous analysis of complex formulations; efficient sample throughput [7]	Increased method complexity; higher risk of co-elution if not rationally designed [6]	Moderate to high; dependent on validation depth [16]
AQbD-guided chromatographic approaches	Systematic method design based on quality-by-design principles	Identification of critical method parameters influencing separation performance [7]	Enhanced understanding of method variability; improved robustness and lifecycle management [7]	Requires advanced experimental planning and statistical tools [11]	High; aligned with contemporary regulatory expectations [16, 17]

6. Comparative Analytical Synthesis of Spectroscopic and Chromatographic Methods

A critical comparison of spectroscopic and chromatographic methods for the simultaneous estimation of telmisartan and amlodipine reveals fundamental differences in analytical philosophy, selectivity mechanisms, and regulatory robustness. While both approaches aim to address the challenges posed by fixed-dose combination analysis, their theoretical foundations and practical implications differ substantially [8, 10].

6.1 Basis of Selectivity and Interference Control

The primary distinction between the two methodological classes lies in the mechanism by which selectivity is achieved. Spectroscopic methods rely on mathematical or chemometric manipulation of overlapping ultraviolet absorption signals to achieve analyte discrimination [1, 4]. In contrast, chromatographic methods achieve selectivity through physical separation of analytes prior to detection, thereby minimizing spectral and matrix-related interference at the detection stage [6]. From a theoretical standpoint, physical separation inherently offers greater resistance to excipient interference and baseline variability compared to purely signal-processing-based approaches [19].

6.2 Sensitivity and Concentration Ratio Considerations

The unequal dose ratio characteristic of telmisartan-amlodipine fixed-dose combinations presents a significant analytical challenge, particularly for spectroscopic methods [27]. Mathematical resolution techniques may struggle to maintain adequate sensitivity for the lower-dose component without compromising accuracy for the higher-dose drug [10]. Chromatographic methods, by contrast, can theoretically accommodate such disparities more effectively through optimized separation and detection conditions, enabling reliable quantification across a broader concentration range [8].

6.3 Robustness and Method Variability

Analytical robustness is influenced by the susceptibility of a method to variations in instrumental and environmental conditions. Spectroscopic methods are theoretically more sensitive to changes in solvent composition, pH, and instrumental noise, particularly when derivative or correction techniques are employed [9]. Chromatographic methods, although more complex, offer greater robustness when critical method parameters are well controlled, especially under pH-optimized and AQbD-guided conditions [7, 17]. This difference has direct implications for method reproducibility across laboratories and analytical platforms [16].

6.4 Regulatory Acceptability and Validation Perspective

From a regulatory perspective, chromatographic methods are generally favored for the assay of fixed-dose combination products due to their higher specificity and alignment with ICH Q2(R1) validation expectations [16]. Spectroscopic methods, while acceptable for routine screening or preliminary analysis, may face limitations in demonstrating specificity and robustness under stringent regulatory scrutiny [10]. Theoretical evaluation suggests that spectroscopic approaches are more likely to require complementary techniques to support regulatory submissions, whereas chromatographic methods can often function as standalone assays [8].

6.5 Practical Utility and Analytical Hierarchy

Despite their limitations, spectroscopic methods retain practical value due to their simplicity, low operational cost, and rapid throughput [10]. These attributes make them suitable for in-process monitoring and routine quality control in settings with limited analytical infrastructure. Chromatographic methods, although resource-intensive, occupy a higher position in the analytical hierarchy due to their superior selectivity, sensitivity, and regulatory acceptance [9]. The choice between these approaches should therefore be guided by analytical objectives, regulatory requirements, and available resources rather than convenience alone [18].

6.6 Integrated Analytical Perspective

In an integrated analytical framework, spectroscopic and chromatographic methods should be viewed as complementary rather than competing approaches. Spectroscopic techniques can serve as efficient preliminary or supportive tools, while chromatographic methods provide definitive quantification and regulatory assurance for telmisartan-amlodipine combination products [8, 16]. This tiered analytical strategy aligns with contemporary quality-focused paradigms in pharmaceutical analysis and supports rational method selection across different stages of product development and quality control [17].

To consolidate the conceptual distinctions between spectroscopic and chromatographic approaches discussed above, a theoretical comparison of their analytical attributes and regulatory relevance is summarized in Table 4.

Table 4: Theoretical comparison of spectroscopic and chromatographic methods for simultaneous estimation of telmisartan and amlodipine.

Analytical attribute	Spectroscopic methods	Chromatographic methods
Basis of selectivity	Achieved through mathematical or chemometric resolution of overlapping UV absorption signals [1, 4]	Achieved through physical separation of analytes prior to detection [6, 8]
Control of spectral and matrix interference	Limited intrinsic interference control; highly dependent on signal processing strategy [10]	Strong interference minimization due to analyte separation and controlled detection conditions [19]
Sensitivity to concentration disparity	Theoretically constrained by unequal dose ratios, particularly for low-dose amlodipine [27]	Better accommodates concentration differences through optimized separation and detection [8]
Robustness to analytical variability	More sensitive to changes in solvent composition, pH, and instrumental noise [9]	Greater robustness when critical chromatographic parameters are well controlled [7, 17]
Validation and regulatory alignment	May face challenges in demonstrating specificity under ICH Q2(R1) expectations [10, 16]	Well aligned with ICH Q2(R1) requirements for specificity and precision [16]
Typical analytical role	Suitable for preliminary analysis, routine screening, or supportive quality control [10]	Preferred for confirmatory analysis, routine QC, and regulatory submissions [8]

7. Future Perspectives and Analytical Outlook

The simultaneous estimation of telmisartan and amlodipine continues to evolve in response to increasing regulatory expectations, formulation complexity, and the growing emphasis on analytical lifecycle management. From a theoretical standpoint, future analytical strategies are expected to move beyond isolated method development toward integrated, knowledge-driven frameworks that emphasize robustness, transferability, and regulatory alignment [16, 17].

7.1 Transition from Empirical to Knowledge-Based Method Design

A notable trend in pharmaceutical analysis is the gradual shift from empirically optimized methods toward analytically rational design approaches. For chromatographic techniques, the increasing adoption of Analytical Quality by Design (AQbD) principles reflects this transition, enabling systematic identification of critical method parameters and their impact on analytical performance [7, 17]. Theoretical integration of AQbD concepts offers improved method understanding and reduced risk of failure during method transfer and lifecycle management, particularly for fixed-dose combinations such as telmisartan-amlodipine [16].

7.2Role of Advanced Data Handling and Chemometrics

In spectroscopic analysis, future developments are likely to emphasize advanced data processing and multivariate modeling to partially overcome inherent limitations associated with spectral overlap [5]. While chemometric-assisted spectroscopic methods remain analytically promising, their broader implementation will depend on improved model transparency, standardization, and regulatory confidence [11]. From a theoretical perspective, harmonization of chemometric validation principles with established regulatory frameworks represents a key challenge and opportunity for expanding the practical utility of these approaches [16].

7.3 Regulatory and Harmonization Considerations

Regulatory agencies increasingly emphasize method robustness, specificity, and lifecycle control over mere compliance with minimum validation criteria [16]. In this context, chromatographic methods are expected to retain primacy for regulatory submissions involving telmisartan-amlodipine combinations, while spectroscopic methods may continue to serve supportive or screening roles [8]. Greater harmonization of analytical expectations across regions may further influence method selection, favoring approaches with well-established regulatory precedents and documented reliability [18].

7.4 Role of Advanced Data Handling and Chemometrics

In spectroscopic analysis, future developments are likely to emphasize advanced data processing and multivariate modeling to partially overcome inherent limitations associated with spectral overlap [5]. While chemometric-assisted spectroscopic methods remain analytically promising, their broader implementation will depend on improved model transparency, standardization, and regulatory confidence [11]. From a theoretical perspective, harmonization of chemometric validation principles with established regulatory frameworks represents a key challenge and opportunity for expanding the practical utility of these approaches [16].

7.5 Regulatory and Harmonization Considerations

Regulatory agencies increasingly emphasize method robustness, specificity, and lifecycle control over mere compliance with minimum validation criteria [16]. In this context, chromatographic methods are expected to retain primacy for regulatory submissions involving telmisartan-amlodipine combinations, while spectroscopic methods may continue to serve supportive or screening roles [8]. Greater harmonization of analytical expectations across regions may further influence method selection, favoring approaches with well-established regulatory precedents and documented reliability [18].

8. Conclusion

This critical review has systematically examined spectroscopic and chromatographic approaches for the simultaneous estimation of telmisartan and amlodipine from a theoretical and analytical perspective. Spectroscopic methods offer simplicity, rapid analysis, and cost efficiency but are fundamentally constrained by spectral overlap, sensitivity disparities, and limited regulatory robustness [10, 27]. Chromatographic methods, particularly RP-HPLC, provide superior selectivity, robustness, and regulatory acceptance due to physical separation of analytes and well-established validation frameworks [8, 16].

The comparative synthesis highlights that no single analytical approach is universally optimal; rather, method selection should be guided by analytical objectives, formulation complexity, regulatory requirements, and available infrastructure. An integrated, tiered analytical strategy—employing spectroscopic methods for preliminary assessment and chromatographic techniques for confirmatory and regulatory purposes—represents a rational and forward-looking paradigm for the quality control of telmisartan-amlodipine fixed-dose combinations [17].

By emphasizing theoretical foundations, critical evaluation, and regulatory relevance, this review aims to support informed analytical decision-making and encourage the adoption of scientifically robust, future-ready analytical methodologies in pharmaceutical analysis.

References

1. Hirave RV, Kasture AV. Simultaneous estimation of telmisartan and amlodipine besylate by first derivative UV spectrophotometric method. Int J Pharm Sci Rev Res. 2014;24(2):169-172.
2. Gupta N, Peepliwal A, Rathore D, Gupta P. Simultaneous spectrophotometric estimation of telmisartan and amlodipine besylate in tablet dosage form. Int J Pharm Biol Res. 2015;3(3):50-54.
3. Karajgi SR, Kalyani P, Mali KK. Simultaneous spectrophotometric estimation of amlodipine besylate and telmisartan in tablet dosage form. Res J Pharm Technol. 2010;3(4):1337-1340.
4. Rane VP, Sangshetti JN, Shinde DB. Simultaneous spectrophotometric estimation of amlodipine besylate and telmisartan by multi-wavelength method. Int J ChemTech Res. 2011;3(3):1274-1278.
5. Khanage SG, Mohite SK, Rajkumar M, Deshmukh KK. Simultaneous estimation of telmisartan, hydrochlorothiazide and amlodipine by chemometric-assisted spectrophotometric methods. Int J Pharm Sci Res. 2018;9(1):360-368.
6. Patil SS, Channabasavaraj KP, Devdhe S. Development and validation of RP-HPLC method for simultaneous estimation of telmisartan and amlodipine besylate in tablet dosage form. Int J Pharm Drug Anal. 2014;2(3):255-260.
7. Prajapati P, Patel A, Shah S. Simultaneous estimation of telmisartan, chlorthalidone, amlodipine besylate and atorvastatin by RP-HPLC method for synchronous assay of multiple fixed-dose combination products using AQbD approach. J Chromatogr Sci. 2023;61(2):160-171.
8. Malekpour A, Farahani M. High-performance liquid chromatography in drug analysis. Drug Test Anal. 2019;11(7):961-970.
9. Ahuja S. Overview: Handbook of pharmaceutical analysis by HPLC. Sep Sci Technol. 2005;6:1-7.
10. Rao RN, Nagaraju V. Development of UV spectrophotometric methods for drug analysis: a review. Austin J Anal Pharm Chem. 2016;3(1):1058.
11. Garshakunta S, Khan SA, Khan NA, Afreen N, Inshera HF, Qureshi MS. Advancements in analytical method development and validation: current trends and challenges. Front J Pharm Sci Res. 2025;8(2):6-12.
12. Chivate ND, Patil S. Development of UV spectrophotometric method for estimation of telmisartan as a pure API. J Pharm Res. 2012;5(6):3331-3333.
13. Rathod S, Patil PM. UV spectrophotometric method development and validation for telmisartan in bulk and tablet dosage form. Int J Pharm Sci Res. 2012;3(10):3936-3939.
14. Pandey A, Sharma S, Singh R, Verma RK. UV spectrophotometric method for estimation of telmisartan in bulk and tablet dosage form. Int J ChemTech Res. 2011;3(2):657-660.
15. Sheetal, Sonia K, Lakshmi KS. Validation of telmisartan by UV spectrophotometry method. Res J Pharm Technol. 2019;12(5):2413-2415.
16. International Council for Harmonisation. ICH Q2(R1): Validation of Analytical Procedures: Text and Methodology. Geneva: ICH; 2005.
17. Borman P, Elder D. Q2(R1) validation of analytical procedures. In: ICH Quality Guidelines: An Implementation Guide. Hoboken: Wiley; 2017. p. 127-166.
18. Haleem RM, Salem MY, Fatahallah FA, Abdelfattah LE. Quality in the pharmaceutical industry: a literature review. Saudi Pharm J. 2015;23(5):463-469.
19. Pedersen-Bjergaard S, Gammelgaard B, Halvorsen TG. Introduction to Pharmaceutical Analytical Chemistry. Hoboken: Wiley; 2019.
20. Beckett AH, Stenlake JB. Practical Pharmaceutical Chemistry. Part II. 4th ed. London: A & C Black; 1988.
21. DrugBank Online. Telmisartan.
22. DrugBank Online. Amlodipine.
23. PubChem. Telmisartan. Compound Summary; CID 65999.
24. PubChem. Amlodipine. Compound Summary; CID 2162.
25. Oparil S, Zannad F. Telmisartan: a new angiotensin II receptor antagonist for hypertension treatment. J Clin Hypertens. 2005;7(12):744-751.
26. Elbardisy S, Ahmed M, Hassan R, *et al*. Single-pill combination therapy of amlodipine, telmisartan, and chlorthalidone in hypertension. Cureus. 2024;16(9):eXXXXX.
27. James PA, Oparil S, Carter BL, *et al*. 2014 evidence-based guideline for the management of high blood pressure in adults